Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase I studies of products utilizing ImmunoGen's TAP technology presented at ASH meeting

Dec. 11, 2009

Responses seen in CLL patients given cenersen added to chemo-immunotherapy

Dec. 11, 2009

JAK2 inhibitor SB-1518 shows promise against hematological malignancies

Dec. 11, 2009

Rufinamide efficacious in adults and children with epilepsy

Dec. 10, 2009

Pfizer's p38 MAPK inhibitor PHA-666859 shows potential to treat diabetic retinopathy

Dec. 10, 2009

CPX-351 safety appears acceptable in older patients with acute myeloid leukemia

Dec. 10, 2009

Pazopanib increases visual acuity in phase II macular degeneration study

Dec. 10, 2009

Promising phase I and II data on foretinib in solid tumor therapy

Dec. 10, 2009

Multiple phase I studies of Exelixis oncolytic products reported

Dec. 10, 2009

Preclinical and early phase I data suggest activity of JI-101 in solid tumors

Dec. 9, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...